HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• Active surveillance, physician–patient communication may redefine role of PSA testing
• Adjuvant and systemic therapy for rare tumors of the uterus and cervix Jubilee Brown, MD; Erin K. Crane, MD; R. Wendel Naumann, MD
• ‘Cautiously reassuring’ picture emerges regarding sickle cell trait health risks Lianne M. Kurina, PhD; D. Alan Nelson, MPAS, PhD
• Dana-Farber surgical oncology chief to assume ASCO presidency in 2018
• New ASH president: 'Extraordinary science' at genomic level must be brought to bedside
• NYU Langone names liver tumor program director
• Payment reform, ‘runaway growth’ of 340B top new Community Oncology Alliance president’s priorities
• University of Chicago researcher receives NCI award
• Avoiding the obvious while running in diminishing circles Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
• FDA accepts biologics license application for proposed biosimilar to Neulasta
• FDA approves Revlimid for myeloma maintenance after stem cell transplant
• FDA grants priority review to inotuzumab ozogamicin for ALL
• Avelumab shows promise in Merkel cell carcinoma
• Changes in depression symptoms may influence lung cancer survival
• Cisplatin therapy effective for men with relapsed stage I seminoma
• Collection of patient-reported outcomes crucial for improving care
• Considering bone marrow blasts from nonerythroid cells improves prognostication of MDS
• Many nonelderly cancer survivors alter prescription drug use to save money
• Most adolescents, young adults not treated with pediatric ALL protocols
• Regular aspirin use may lower risk for pancreatic cancer
• Scalp-cooling caps may reduce hair loss for women with breast cancer
• Sickle cell trait unrelated to fitness level, heart failure
• SIOP scale best detects ototoxicity in children who receive cisplatin chemotherapy
• Upfront surgery does not improve OS for patients with HPV–negative OPSCC
• Reduced abiraterone acetate dose with low-fat meal maintains efficacy, saves costs
• Use of antibiotics could reduce efficacy of immunotherapy
• Is genetic testing sophisticated enough to make PSA screening viable for mainstream use?